Evidence map›Paper›PMID 41573737›Full record

ArticleFrontiers in pharmacology2025

Venetoclax concentration affects the incidence of haematological adverse events in patients with acute myeloid leukaemia.

Jing Chen, Xi Yang, Jingxian Xie, Lijuan Zhang, Lu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing Chen *Department of Pharmacy, Guangyuan Central Hospital of Sichuan Province, Guangyuan, China.
Xi Yang *School of Medicine, University of Electronic Science and Technology of China, Department of Hematology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu, China.
Jingxian XieDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lijuan ZhangDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lu ChenDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Venetoclax (VEN) demonstrates considerable inter-individual variability in drug exposure, and its pharmacokinetics are substantially influenced by concurrent administration of CYP3A inhibitors. This study explores the relationship between VEN exposure and the incidence of haematological adverse events (AEs) in patients by quantifying systemic VEN concentrations. Methods: We retrospectively analyzed data from 114 patients who received VEN therapy. Among these, 52 were treated with VEN combined with azacitidine (AZA, days 1-7), 20 received VEN + AZA combined with omeprazole (OPZ), 20 received VEN + AZA combined with voriconazole (VCZ), and 22 received VEN + AZA combined with posaconazole (PCZ). High-performance liquid chromatography was used to determine the plasma steady-state C Results: The effect of combined medication on VEN concentration was as follows: VEN + PCZ group/VEN + VCZ group > VEN + OPZ group > VEN group. Increased VEN concentration increased the incidence of Grade 3 or higher haematological AEs. CYP3A inhibitors increased VEN levels, thereby increasing the risk of AEs. A VEN C Conclusion: VEN concentration is correlated with the occurrence of haematological AEs, and VEN concentrations can be used to predict the occurrence of haematological AEs.

Indexed as

combination medicationconcentrationCYP3A inhibitorshaematological adverse eventsvenetoclax

Identifiers

PMID41573737
PMCPMC12819687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.